Viet Tran, MD
Clinical Cardiac Electrophysiology · Chandler, AZNPI 1235465311
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Boston Scientific at 32.9% of the total. Reporting peaked in 2023 at $16,111 and has fallen 81.2% since, to $3,034 in 2025.
Across 374 payments — averaging $125.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- Medical Device Business Services, Inc.$14K
- Abbott$10K
- Biosense Webster, Inc.$2K
- Biotronik Inc.$1K
- Medtronic$985
- plus $3K from 24 others
What the payments were for
- Consulting fees$11,58825%
- Speaking & faculty fees$11,55025%
- Travel & lodging$5,90713%
- Food & beverage$17,94338%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 109 | $15,457 |
| Medical Device Business Services, Inc. | 4 | $14,247 |
| Abbott | 106 | $10,023 |
| Biosense Webster, Inc. | 35 | $1,882 |
| Biotronik Inc. | 14 | $1,366 |
| Medtronic(3 entities) | 8 | $985 |
| Impulse Dynamics (USA) Inc. | 25 | $533 |
| Philips North America LLC | 7 | $406 |
| Acutus Medical, Inc. | 3 | $393 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $309 |
| Atricure, Inc. | 3 | $239 |
| Cardiva Medical, Inc. | 6 | $206 |
| Novartis | 10 | $168 |
| Amgen | 3 | $156 |
| Actelion Pharmaceuticals US, Inc. | 4 | $92 |
| EBR Systems, Inc. | 1 | $74 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Elutia, Inc. | 3 | $41 |
| Johnson & Johnson | 2 | $40 |
| Irhythm Technologies, Inc. | 3 | $37 |
| AstraZeneca | 2 | $34 |
| Bardy Diagnostics, Inc. | 2 | $30 |
| Terumo Medical Corporation | 1 | $30 |
| Pfizer | 2 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Akcea Therapeutics, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Abiomed | 1 | $21 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$14,487
- RHYTHMIA$4,411
- EMBLEM$3,750
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$3,000
- AVEIR$2,282
- Quadra Assura CRT Defibrillator$1,632
- GALLANT$742
- ENSITE$727
- WATCHMAN Access System$723
- Assurity Pacemaker$680
- GENERAL BRADY$625
- AMPLATZER AMULET$526
- GENERAL - THERAPIES$501
- NA$313
- OPTIMIZER$295
- QDOT MICRO$293
- ASSURITY$281
- ENSITE PRECISION$180
- Micra$170
- Confirm Rx$167
How this compares
$46,987 in reported general payments places this provider in the 65th percentile of 80 clinical cardiac electrophysiology providers in Arizona.
See all clinical cardiac electrophysiology providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 172 | $208,011 |
| XareltoRivaroxaban | 57 | $59,948 |
| EntrestoSacubitril/Valsartan | 50 | $57,649 |
| Metoprolol Succinate | 157 | $2,232 |
| Amiodarone Hcl | 72 | $1,013 |
| Flecainide Acetate | 34 | $755 |
| Atorvastatin Calcium | 57 | $732 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 29 | $674 |
| Midodrine Hcl | 14 | $658 |
| Carvedilol | 38 | $656 |
| Digoxin | 32 | $630 |
| ClopidogrelClopidogrel Bisulfate | 39 | $626 |
| Losartan Potassium | 65 | $491 |
| Bumetanide | 24 | $470 |
| Hydralazine Hcl | 46 | $420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25 | $208,011172 claims |
| Johnson & JohnsonXarelto | $40 | $59,94857 claims |
| NovartisEntresto | $168 | $57,64950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 80 clinical cardiac electrophysiology providers in Arizona.
Other clinical cardiac electrophysiology in Chandler
- Eric RobinsonChandler$84K
- Jaskanwal BislaChandler$70K
- Drory TendlerChandler$57K
- Osama NiaziChandler$47K
- Huy PhanChandler$28K
- Himal ShahChandler$18K
- Akash MakkarPhoenix$318K
- Jonathan WeissPhoenix$290K
- Ashish SadhuScottsdale$264K
- Yoaav KrauthammerPhoenix$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.